Key statistics dashboard for Acumen Pharmaceuticals, Inc. (ABOS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
Stock Data
| Price | $2.61 |
| Market Cap | $189M |
| Beta | 0.34 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.76 |
| Price / Book | 3.65 |
| P/S | 0.00 |
| P/FCF | -2.27 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.47 |
| Quick Ratio | 2.47 |
| Cash Ratio | 1.27 |
| Debt / Equity | 0.55 |
| Debt / Assets | 27.21% |
| Interest Coverage | -24.41 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.79 |
| Cash per share | 1.53 |
| FCF per share | -1.27 |
| Tangible Book Value per share | 0.79 |
| Dividend per share | 0.00 |
Related companies: ACTU · AGEN · ALEC · FATE · INO · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of ABOS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks